An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (INCB 39110-207)

June 22, 2018
https://clinicaltrials.gov/ct2/show/NCT02917993
Cancer - Lung
Principal Investigator: Igor I Rybkin, MD
lung cancer, lung, cancer, INCB39110-207, Incyte
Accepting Participants